Upstream Bio公布Verekitug针对重症哮喘与CRSwNP的关键性III期临床开发计划

美股速递

Sep 01

Upstream Bio今日宣布，其核心在研药物Verekitug在重症哮喘及慢性鼻窦炎伴鼻息肉（CRSwNP）两大适应症上，均已锁定关键性III期临床开发路径。这一战略布局标志着该公司在呼吸与炎症疾病领域的研发管线迈入全新阶段。

具体而言，Verekitug作为一款备受瞩目的候选疗法，其设计初衷直指重度哮喘患者群体中尚未被满足的迫切医疗需求。与此同时，针对CRSwNP这一同样困扰大量患者的慢性炎症性疾病，Upstream Bio亦同步规划了严谨的注册性试验方案。此举不仅展现了公司对Verekitug潜力的坚定信心，也反映了其在复杂免疫通路调控上的持续深耕。

从时间维度与执行节奏来看，两项III期研究将并行推进，旨在通过大规模、多中心的数据收集，全面评估药物的疗效与长期安全性。业界普遍认为，若能顺利达成主要终点，Verekitug有望重塑现有治疗格局，为那些对标准疗法应答不佳的患者提供新的曙光。

目前，公司正积极筹备试验启动所需的相关工作，包括研究中心遴选及监管沟通等环节。管理层强调，这一里程碑式的进展，离不开前期II期数据所奠定的坚实基础。未来数月内，更多关于试验设计细节及入组标准的更新信息，预计将陆续对外披露。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1174103724"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174103724\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174103724?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-01 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174103724","market":"us","top_or_hot":-1,"title":"Upstream Bio公布Verekitug针对重症哮喘与CRSwNP的关键性III期临床开发计划","media":"美股速递","content":"<p>Upstream Bio今日宣布，其核心在研药物Verekitug在重症哮喘及慢性鼻窦炎伴鼻息肉（CRSwNP）两大适应症上，均已锁定关键性III期临床开发路径。这一战略布局标志着该公司在呼吸与炎症疾病领域的研发管线迈入全新阶段。</p>\n<p>具体而言，Verekitug作为一款备受瞩目的候选疗法，其设计初衷直指重度哮喘患者群体中尚未被满足的迫切医疗需求。与此同时，针对CRSwNP这一同样困扰大量患者的慢性炎症性疾病，Upstream Bio亦同步规划了严谨的注册性试验方案。此举不仅展现了公司对Verekitug潜力的坚定信心，也反映了其在复杂免疫通路调控上的持续深耕。</p>\n<p>从时间维度与执行节奏来看，两项III期研究将并行推进，旨在通过大规模、多中心的数据收集，全面评估药物的疗效与长期安全性。业界普遍认为，若能顺利达成主要终点，Verekitug有望重塑现有治疗格局，为那些对标准疗法应答不佳的患者提供新的曙光。</p>\n<p>目前，公司正积极筹备试验启动所需的相关工作，包括研究中心遴选及监管沟通等环节。管理层强调，这一里程碑式的进展，离不开前期II期数据所奠定的坚实基础。未来数月内，更多关于试验设计细节及入组标准的更新信息，预计将陆续对外披露。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstream Bio公布Verekitug针对重症哮喘与CRSwNP的关键性III期临床开发计划</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstream Bio公布Verekitug针对重症哮喘与CRSwNP的关键性III期临床开发计划\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-09-01 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Upstream Bio今日宣布，其核心在研药物Verekitug在重症哮喘及慢性鼻窦炎伴鼻息肉（CRSwNP）两大适应症上，均已锁定关键性III期临床开发路径。这一战略布局标志着该公司在呼吸与炎症疾病领域的研发管线迈入全新阶段。</p>\n<p>具体而言，Verekitug作为一款备受瞩目的候选疗法，其设计初衷直指重度哮喘患者群体中尚未被满足的迫切医疗需求。与此同时，针对CRSwNP这一同样困扰大量患者的慢性炎症性疾病，Upstream Bio亦同步规划了严谨的注册性试验方案。此举不仅展现了公司对Verekitug潜力的坚定信心，也反映了其在复杂免疫通路调控上的持续深耕。</p>\n<p>从时间维度与执行节奏来看，两项III期研究将并行推进，旨在通过大规模、多中心的数据收集，全面评估药物的疗效与长期安全性。业界普遍认为，若能顺利达成主要终点，Verekitug有望重塑现有治疗格局，为那些对标准疗法应答不佳的患者提供新的曙光。</p>\n<p>目前，公司正积极筹备试验启动所需的相关工作，包括研究中心遴选及监管沟通等环节。管理层强调，这一里程碑式的进展，离不开前期II期数据所奠定的坚实基础。未来数月内，更多关于试验设计细节及入组标准的更新信息，预计将陆续对外披露。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UPB","symbol_name":"UpStream Bio Inc.","start_time":0,"source_url":"","article_id":"1174103724","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174103724","pubTimestamp":1788260477,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Upstream Bio今日宣布，其核心在研药物Verekitug在重症哮喘及慢性鼻窦炎伴鼻息肉两大适应症上，均已锁定关键性III期临床开发路径。这一战略布局标志着该公司在呼吸与炎症疾病领域的研发管线迈入全新阶段。具体而言，Verekitug作为一款备受瞩目的候选疗法，其设计初衷直指重度哮喘患者群体中尚未被满足的迫切医疗需求。与此同时，针对CRSwNP这一同样困扰大量患者的慢性炎症性疾病，Upstream Bio亦同步规划了严谨的注册性试验方案。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"UPB":"UpStream Bio Inc.","BK4139":"生物科技"},"translate_title":"Upstream Bio announces Verekitug's pivotal Phase III clinical development plan for severe asthma and CRSwNP","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UPB":1},"content_text":"Upstream Bio今日宣布，其核心在研药物Verekitug在重症哮喘及慢性鼻窦炎伴鼻息肉（CRSwNP）两大适应症上，均已锁定关键性III期临床开发路径。这一战略布局标志着该公司在呼吸与炎症疾病领域的研发管线迈入全新阶段。\n具体而言，Verekitug作为一款备受瞩目的候选疗法，其设计初衷直指重度哮喘患者群体中尚未被满足的迫切医疗需求。与此同时，针对CRSwNP这一同样困扰大量患者的慢性炎症性疾病，Upstream Bio亦同步规划了严谨的注册性试验方案。此举不仅展现了公司对Verekitug潜力的坚定信心，也反映了其在复杂免疫通路调控上的持续深耕。\n从时间维度与执行节奏来看，两项III期研究将并行推进，旨在通过大规模、多中心的数据收集，全面评估药物的疗效与长期安全性。业界普遍认为，若能顺利达成主要终点，Verekitug有望重塑现有治疗格局，为那些对标准疗法应答不佳的患者提供新的曙光。\n目前，公司正积极筹备试验启动所需的相关工作，包括研究中心遴选及监管沟通等环节。管理层强调，这一里程碑式的进展，离不开前期II期数据所奠定的坚实基础。未来数月内，更多关于试验设计细节及入组标准的更新信息，预计将陆续对外披露。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}